Charles River Laboratories International (NYSE:CRL) Releases FY 2025 Earnings Guidance

Charles River Laboratories International (NYSE:CRL) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 9.100-9.600 for the period, compared to the consensus estimate of 9.600. The company issued revenue guidance of $3.8 billion-$3.9 billion, compared to the consensus revenue estimate of $3.9 billion.

Charles River Laboratories International Stock Up 1.7 %

Shares of CRL stock opened at $154.63 on Wednesday. Charles River Laboratories International has a 12 month low of $150.79 and a 12 month high of $275.00. The stock has a market cap of $7.91 billion, a P/E ratio of 19.35, a P/E/G ratio of 5.91 and a beta of 1.37. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. The company has a 50 day simple moving average of $174.59 and a two-hundred day simple moving average of $189.16.

Analyst Upgrades and Downgrades

A number of analysts have commented on CRL shares. UBS Group reaffirmed a “neutral” rating and set a $185.00 target price (down from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. TD Cowen increased their price objective on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research note on Monday, November 11th. JPMorgan Chase & Co. reduced their price objective on shares of Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating for the company in a research note on Monday, February 3rd. Barclays reduced their price objective on shares of Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating for the company in a research note on Tuesday. Finally, StockNews.com cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Thursday, November 7th. Three research analysts have rated the stock with a sell rating, thirteen have given a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $197.64.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).